WallStreetZenWallStreetZen

NASDAQ: OPTN
Optinose Inc Stock

$1.03+0.14 (+15.73%)
Updated Apr 22, 2024
OPTN Price
$1.03
Fair Value Price
N/A
Market Cap
$116.03M
52 Week Low
$0.86
52 Week High
$2.10
P/E
-3.22x
P/B
-1.34x
P/S
2.04x
PEG
N/A
Dividend Yield
N/A
Revenue
$70.99M
Earnings
-$35.48M
Gross Margin
87.8%
Operating Margin
-22.48%
Profit Margin
-50%
Debt to Equity
-2.24
Operating Cash Flow
-$21M
Beta
0.87
Next Earnings
May 9, 2024
Ex-Dividend
N/A
Next Dividend
N/A

OPTN Overview

OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It is also developing OPN-019 that combines liquid EDS device with an antiseptic. The company has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail; and Inexia Limited to develop, manufacture, import, and sale products containing orexin receptor agonist and/or orexin receptor positive modulator molecules for the treatment, diagnosis, or prevention of human diseases or conditions associated primarily with orexin receptor agonism and orexin receptor positive modulation. OptiNose, Inc. was founded in 2000 and is headquartered in Yardley, Pennsylvania.

Zen Score

Industry Average (25)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how OPTN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

OPTN is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
OPTN is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
OPTN's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more OPTN due diligence checks available for Premium users.

Be the first to know about important OPTN news, forecast changes, insider trades & much more!

OPTN News

Valuation

OPTN fair value

Fair Value of OPTN stock based on Discounted Cash Flow (DCF)
Price
$1.03
Fair Value
-$0.04
Undervalued by
2,413.12%
OPTN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

OPTN price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-3.22x
Industry
46.47x
Market
41x

OPTN price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
-1.34x
Industry
2.04x

OPTN's financial health

Profit margin

Revenue
$19.9M
Net Income
-$10.0M
Profit Margin
-50.2%
OPTN's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
OPTN's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$107.7M
Liabilities
$194.3M
Debt to equity
-2.24
OPTN's short-term liabilities ($176.52M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
OPTN's short-term assets ($105.33M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
OPTN's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
OPTN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
$6.9M
Investing
-$73.0k
Financing
$4.0k
OPTN's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

OPTN vs Pharmaceutical Stocks

TickerMarket Cap1d %P/EP/B
OPTN$116.03M+15.21%-3.22x-1.34x
INCR$115.30M0.00%N/A0.86x
CRDL$115.02M-0.56%-5.43x5.54x
EBS$112.76M+5.88%-0.15x0.17x
ZOM$127.39M+4.84%-3.71x0.53x

Optinose Stock FAQ

What is Optinose's quote symbol?

(NASDAQ: OPTN) Optinose trades on the NASDAQ under the ticker symbol OPTN. Optinose stock quotes can also be displayed as NASDAQ: OPTN.

If you're new to stock investing, here's how to buy Optinose stock.

What is the 52 week high and low for Optinose (NASDAQ: OPTN)?

(NASDAQ: OPTN) Optinose's 52-week high was $2.10, and its 52-week low was $0.86. It is currently -50.95% from its 52-week high and 20.47% from its 52-week low.

How much is Optinose stock worth today?

(NASDAQ: OPTN) Optinose currently has 112,651,740 outstanding shares. With Optinose stock trading at $1.03 per share, the total value of Optinose stock (market capitalization) is $116.03M.

Optinose stock was originally listed at a price of $19.00 in Oct 13, 2017. If you had invested in Optinose stock at $19.00, your return over the last 6 years would have been -94.58%, for an annualized return of -38.48% (not including any dividends or dividend reinvestments).

How much is Optinose's stock price per share?

(NASDAQ: OPTN) Optinose stock price per share is $1.03 today (as of Apr 22, 2024).

What is Optinose's Market Cap?

(NASDAQ: OPTN) Optinose's market cap is $116.03M, as of Apr 23, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Optinose's market cap is calculated by multiplying OPTN's current stock price of $1.03 by OPTN's total outstanding shares of 112,651,740.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.